Cover for July

A recap of the FDA submissions and regulatory decisions in pediatrics from January 2025.

The primary and all key secondary endpoints were met compared to cream vehicle in the phase 3 DELTA TEEN trial.

As a biosimilar to Actemra, tocilizumab-anoh in both IV and SC formulation is approved to treat rheumatoid arthritis, pJIA, sJIA, COVID-19, and giant cell arteritis.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.